The risk of atrial fibrillation in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1091-1095

  Kim, Seoyoung C ^a   Liu, Jun ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASES; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNITED STATES;

CARDIOVASCULAR DISEASE; INFLAMMATION; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UNITED STATES;

EID: 84899971423     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203343     Document Type: Article

References (27)

1. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99: 237-42. (Pubitemid 29056365)
2. Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-9. (Pubitemid 27152782)
3. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98: 476-84.
4. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26: 2083-92. (Pubitemid 41408600)
5. Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49: 1642-8. (Pubitemid 46551628)
6. Guo Y, Lip G, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012;60: 2263-70.
7. Conen D, Ridker P, Everett B, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010;31: 1730-6.
8. Schnabel R, Larson M, Yamamoto J, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009;104: 92-6.
9. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69: 1920-5.
10. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107: 1303-7. (Pubitemid 36314415)
11. Del Rincón I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48: 1833-40. (Pubitemid 36828677)
12. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68: 1395-400.
13. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271: 840-4.
14. Corrao S, Messina S, Pistone G, et al. Heart involvement in Rheumatoid Arthritis: Systematic review and meta-analysis. Int J Cardiol Published Online First: 14 June 2012. doi:10.1016/j.ijcard.2012.05.057
15. Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012;344:e1257.
16. Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
17. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007;167: 246-52.
18. Gagne JJ, Glynn RJ, Avorn J, et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64: 749-59.
19. Rothman K, Greenland S, Lash T. Modern epidemiology. 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008.
20. Cox D. Regression models and life-tables. J R Stat Soc 1972;34: 187-220.
21. Peña JM, MacFadyen J, Glynn RJ, et al. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012;33: 531-7.
22. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93: 780-2. (Pubitemid 38338579)
23. Nyrnes A, Njølstad I, Mathiesen E, et al. Inflammatory Biomarkers as Risk Factors for Future Atrial Fibrillation. An Eleven-Year Follow-Up of 6315 Men and Women: The Tromsø Study. Gend Med 2012:Epub ahead of print.
24. Christiansen C, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009;169: 1677-83.
25. Schmidt M, Christiansen C, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011;343.
26. Cardiovascular Inflammation Reduction Trial (CIRT). November 14, 2012 [cited 2012 December 31]; Available from: http://clinicaltrials.gov/ct2/show/ NCT01594333
27. Ridker P. Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates? Curr Atheroscler Rep 2013;15:295.